ReviewArthritis research & therapy2010
T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?
Review in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 93 citations in OpenAlex.
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- M-CSF, inducing CD163 macrophages, is associated with severity and prognosis of glomerulonephritis in microscopic polyangiitis.Arthritis research & therapy · 2025Article
- T-cell immunity in the experimental autoimmune vasculitis rat model.Journal of translational autoimmunity · 2025Article
- Advances in the treatment of ANCA-associated vasculitis.Nature reviews. Rheumatology · 2025Review
- Immunopathology of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.International journal of molecular sciences · 2025Review
- Garcin Syndrome in a Patient with Hypertrophic Pachymeningitis Following Otitis Media with Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (OMAAV).Internal medicine (Tokyo, Japan) · 2025Article
- Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression.Journal of nephrology · 2023Article
- New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond.Antibodies (Basel, Switzerland) · 2023Review
- Type of ANCA May Be Indispensable in Distinguishing Subphenotypes of Different Clinical Entities in ANCA-Associated Vasculitis.Life (Basel, Switzerland) · 2022Review
- Th17.1 lymphocytes: emerging players in the orchestra of immune-mediated inflammatory diseases.Clinical rheumatology · 2022Review
- Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders.Biomolecules · 2021Review
- Granulomatous Inflammation in ANCA-Associated Vasculitis.International journal of molecular sciences · 2021Review
- Human Proteinase 3, an important autoantigen of c-ANCA associated vasculitis, shares cross-reactive epitopes with serine protease allergens from mites: anF1000Research · 2021Article
- Immunopathogenesis of ANCA-Associated Vasculitis.International journal of molecular sciences · 2020Review
- Checkpoint inhibitor-related renal vasculitis and use of rituximab.Journal for immunotherapy of cancer · 2020Article
- Exploring Frequencies of Circulating Specific Th17 Cells against Myeloperoxidase and Proteinase 3 in ANCA Associated Vasculitis.International journal of molecular sciences · 2019Article
- T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach.Clinical kidney journal · 2019Article
- Serum interleukin-21 positivity could indicate the current activity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study.Clinical rheumatology · 2019Article
- The Co-inhibitor BTLA Is Functional in ANCA-Associated Vasculitis and Suppresses Th17 Cells.Frontiers in immunology · 2019Article
- Phenotypic Characterization of Circulating CD4Journal of immunology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA) - associated vasculitis (AAV) is a life-threatening autoimmune disease characterized by an antibody-mediated glomerulonephritis and necrotizing vasculitis. Apart from antibodies, T cells are also involved in disease pathogenesis. This review stresses the hallmarks of T cell-mediated pathology in AAV and highlights the characteristics of lesional and circulating T cells in the immune response in AAV. Circulating effector T-cell populations are expanded and are in a persistent state of activation. Circulating regulatory T-cell subsets are less well characterized but seem to be impaired in function. Lesional effector T cells are present in granulomas, vasculitic lesions, and nephritis. Lesional T cells usually show pro-inflammatory properties and promote granuloma formation. Apart from T cells, dendritic cells are abundantly present at the sites of inflammation and locally orchestrate the immune response. Targeting the above-mentioned T cell-mediated disease mechanisms will potentially provide powerful therapeutic tools for AAV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.